Skip to main content
. 2014 Dec 18;6(5):2779–2793. doi: 10.18632/oncotarget.2995

Figure 2. Sema6A and Mical1 are highly expressed in vivo in B-RAFV600E compared to WT melanomas.

Figure 2

(A-B) Expression of SEMA6A and MICAL1 mRNA was examined by qRT-PCR on lymph node biopsies from patients carrying BRAFV600E or WT tumors (left and right graphs). Representative Sema6A and Mical1 IHC on sections derived from same samples. Secondary antibody was used as internal control. Scale bar 30 μm.